ArticleBMC anesthesiology2026
VIDD or CIADD? The ventilator remains a bona fide culprit.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosà and colleagues recently proposed that mechanical ventilation (MV) may not be the primary driver of diaphragm dysfunction in critically ill patients, advocating the term "critical illness-associated diaphragm dysfunction" (CIADD) over "ventilator-induced diaphragm dysfunction" (VIDD). While we support distinguishing VIDD from CIADD, we contend that the review's central conclusion underestimates the causal role of MV itself.This commentary addresses three questions in turn. First, does MV injure the diaphragm under controlled conditions? Here the evidence is strong: brain-dead donor studies-dismissed by the authors as a "unique patient category"-are a uniquely informative, though not pure, human model of controlled MV exposure, and their dismissal creates an unfalsifiable position. Second, how much does MV contribute to diaphragm dysfunction in critically ill patients? This is considerably less certain: the molecular abnormalities observed in critically ill patients (ubiquitin-proteasome activation, RyR1 calcium leak, mitochondrial oxidative stress) coincide with pathways that MV reliably induces in controlled animal experiments, providing biological plausibility-though not proof-that MV contributes to the molecular phenotype of critical illness. Third, do MV and critical illness interact? We propose that CIADD should serve as an umbrella term encompassing VIDD as a distinct mechanistic subtype-rather than replacing it-analogous to how "pneumonia" subsumes VAP, HAP, and CAP, and we propose three differentiated model types for future research: pure VIDD models, pure CIADD models, and combined models with factorial design.VIDD and CIADD are mechanistically distinct but interacting entities. Future research should employ models that minimize confounding from critical illness to isolate ventilation-specific injury pathways. Importantly, establishing that VIDD exists is not equivalent to establishing that preventing VIDD is beneficial; clinical trials are needed to demonstrate the feasibility and benefit of diaphragm-protective strategies. Diminishing MV's role risks undermining the mechanistic foundation of diaphragm-protective ventilation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.